SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-006053 to Corbus Pharmaceuticals Holdings, Inc. (CRBP) (CIK 0001595097) (CRBP)

Corbus Pharmaceuticals Holdings, Inc. (CRBP) (CIK 0001595097)
Date: June 7, 2023 · CIK: 0001595097 · Accession: 0000000000-23-006053

AI Filing Summary & Sentiment

File numbers found in text: 333-272314

Date
June 7, 2023
Author
Not clearly detected
Form
UPLOAD
Company
Corbus Pharmaceuticals Holdings, Inc. (CRBP) (CIK 0001595097)

Letter

United States securities and exchange commission logo June 7, 2023 Sean Moran Chief Financial Officer Corbus Pharmaceuticals Holdings, Inc. 500 River Ridge Drive Norwood, MA 02062 Re:Corbus Pharmaceuticals Holdings, Inc. Registration Statement on Form S-3 Filed June 1, 2023 File No. 333-272314 Dear Sean Moran: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Michael Lerner

Show Raw Text
United States securities and exchange commission logo
June 7, 2023
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals Holdings, Inc.
500 River Ridge Drive
Norwood, MA 02062
Re:Corbus Pharmaceuticals Holdings, Inc.
Registration Statement on Form S-3
Filed June 1, 2023
File No. 333-272314
Dear Sean Moran:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Michael Lerner